Entropy Neurodynamics trial reports 74% episode reduction

• All patients in the first cohort achieved a 74% reduction in binge eating episodes.
• The company share price remained steady following the release of the clinical data.
• The clinical outcomes support expanding the intravenous platform into other neuropsychiatric conditions.

Entropy Neurodynamics (ASX:ENP) reported that all patients in its initial trial cohort achieved a 74% reduction in binge eating episodes.

The clinical results contrast with traditional oral treatments that often show high patient variability within the market.

The company stated that half of the patients in this first group reached complete clinical remission during the study.

An independent monitoring board endorsed moving to the second cohort without modifications to the treatment protocol.

Following the announcement, the Entropy share price was unchanged at $0.15.

The business plans to expand its intravenous platform into additional neuropsychiatric conditions later this year.

Final study results for the fully enrolled second patient cohort are expected in the fourth quarter of 2026.